Zurich Cantonal Bank’s CytomX Therapeutics CTMX Stock Holding History

Zurich Cantonal Bank’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$299K	Buy	79,816 +31,828	+66%	+$122K	﹤0.01%	2184
2026 Q1	$226K	Buy	+47,988	New	+$244K	﹤0.01%	2206
2021 Q4	–	Sell	-5,922	Closed	-$30K	–	2912
2021 Q3	$30K	Hold	5,922	–	–	﹤0.01%	2738
2021 Q2	$37K	Hold	5,922	–	–	﹤0.01%	2512
2021 Q1	$46K	Hold	5,922	–	–	﹤0.01%	2403
2020 Q4	$39K	Hold	5,922	–	–	﹤0.01%	2491
2020 Q3	$39K	Hold	5,922	–	–	﹤0.01%	2324
2020 Q2	$49K	Buy	5,922 +3,469	+141%	+$32.2K	﹤0.01%	2216
2020 Q1	$19K	Hold	2,453	–	–	﹤0.01%	2353
2019 Q4	$20K	Hold	2,453	–	–	﹤0.01%	2502
2019 Q3	$18K	Hold	2,453	–	–	﹤0.01%	2472
2019 Q2	$28K	Hold	2,453	–	–	﹤0.01%	2347
2019 Q1	$26K	Hold	2,453	–	–	﹤0.01%	2326
2018 Q4	$37K	Hold	2,453	–	–	﹤0.01%	2193
2018 Q3	$45K	Hold	2,453	–	–	﹤0.01%	2203
2018 Q2	$56K	Sell	2,453 -838	-25%	-$21.4K	﹤0.01%	2055
2018 Q1	$94K	Hold	3,291	–	–	﹤0.01%	1628
2017 Q4	$69K	Buy	+3,291	New	+$68.2K	﹤0.01%	1812

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Zurich Cantonal Bank's CTMX Position: Q2 2026 in Review

Zurich Cantonal Bank increased its CytomX Therapeutics (CTMX) stake by 66% in Q2 2026, buying an estimated $122K and bringing the position to 79,816 shares worth $299K. The position accounts for ﹤0.01% of the portfolio, ranked #2184.

Zurich Cantonal Bank first reported a position in CTMX in Q4 2017 and has held it in 18 quarters since. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Zurich Cantonal Bank held 79,816 shares of CytomX Therapeutics worth $299K as of Q2 2026.
Zurich Cantonal Bank bought 31,828 CytomX Therapeutics shares in Q2 2026, an estimated $122K.
CytomX Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2184 holding.
Zurich Cantonal Bank first reported a position in CytomX Therapeutics in Q4 2017 and has held it in 18 quarters since.
178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.